4D Molecular Therapeutics, Inc. (FDMT)
Largest Insider Buys in Sector
FDMT Stock Price History Chart
FDMT Stock Performance
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Insider Activity of 4D Molecular Therapeutics, Inc.
Over the last 12 months, insiders at 4D Molecular Therapeutics, Inc. have bought $0 and sold $4.4M worth of 4D Molecular Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at 4D Molecular Therapeutics, Inc. have bought $44.27M and sold $5.88M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 850,000 shares for transaction amount of $13.6M was made by VIKING GLOBAL INVESTORS LP (10 percent owner) on 2023‑05‑09.
List of Insider Buy and Sell Transactions, 4D Molecular Therapeutics, Inc.
| 2024-09-16 | Sale | Chief Legal Officer | 500 0.001% | $16.33 | $8,165 | -51.46% | ||
| 2024-08-19 | Sale | Chief Legal Officer | 500 0.001% | $15.00 | $7,500 | -43.03% | ||
| 2024-07-16 | Sale | Chief Legal Officer | 1,750 0.0044% | $27.11 | $47,443 | -66.56% | ||
| 2024-07-11 | Sale | Chief Legal Officer | 1,996 0.0046% | $25.00 | $49,900 | 0.00% | ||
| 2024-07-10 | Sale | Chief Executive Officer | 12,923 0.0268% | $22.49 | $290,598 | 0.00% | ||
| 2024-07-01 | Sale | Chief Legal Officer | 4,248 0.0084% | $21.36 | $90,758 | 0.00% | ||
| 2024-06-24 | Sale | Chief Executive Officer | 12,930 0.0248% | $23.10 | $298,711 | -61.16% | ||
| 2024-06-17 | Sale | Chief Legal Officer | 1,750 0.0034% | $23.71 | $41,494 | -61.09% | ||
| 2024-05-16 | Sale | Chief Legal Officer | 1,750 0.0034% | $25.45 | $44,541 | -45.59% | ||
| 2024-04-16 | Sale | Chief Legal Officer | 1,750 0.0034% | $25.74 | $45,045 | -43.59% | ||
| 2024-04-01 | Sale | Chief Legal Officer | 8,153 0.0173% | $31.78 | $259,102 | -49.02% | ||
| 2024-03-27 | Sale | Chief Legal Officer | 5,833 0.0114% | $35.04 | $204,410 | -57.29% | ||
| 2024-03-18 | Sale | Chief Legal Officer | 1,750 0.0035% | $31.27 | $54,723 | -49.98% | ||
| 2024-02-27 | Sale | Chief Legal Officer | 1,909 0.0039% | $30.00 | $57,270 | -45.29% | ||
| 2024-02-16 | Sale | Chief Legal Officer | 1,750 0.0036% | $27.67 | $48,423 | -37.27% | ||
| 2024-02-08 | Sale | Chief Executive Officer | 92,001 0.3275% | $27.13 | $2.5M | -32.06% | ||
| 2024-02-08 | Sale | Chief Legal Officer | 1,996 0.0072% | $27.50 | $54,890 | -32.06% | ||
| 2024-02-05 | Sale | Chief Medical Officer | 6,552 0.0258% | $30.05 | $196,888 | -42.64% | ||
| 2024-01-23 | Sale | Chief Executive Officer | 5,696 0.0133% | $18.41 | $104,851 | -0.19% | ||
| 2024-01-05 | Sale | Chief Executive Officer | 28,237 0.0659% | $19.57 | $552,478 | -5.17% |
Insider Historical Profitability
| Kirn David | Chief Executive Officer | 1059153 2.2912% | $4.66 | 0 | 14 | |
| Bizily Scott | Chief Legal Officer | 6781 0.0147% | $4.66 | 0 | 19 | |
| Kim Robert Young | Chief Medical Officer | 1043 0.0023% | $4.66 | 0 | 1 | |
| VIKING GLOBAL INVESTORS LP | 10 percent owner | 4247914 9.1891% | $4.66 | 2 | 1 | <0.0001% |
| YAO TONY DUNG LING | director | 1060880 2.2949% | $4.66 | 1 | 0 | <0.0001% |
| SCHAFFER DAVID | director | 901215 1.9495% | $4.66 | 0 | 7 | |
| MILLIGAN JOHN F | director | 100000 0.2163% | $4.66 | 1 | 0 | <0.0001% |
| Kamal Fariborz | See Remarks | 4347 0.0094% | $4.66 | 1 | 0 | <0.0001% |
| Chacko Jacob | director | 0 0% | $4.66 | 0 | 1 |
Institutional Investor Ownership
| RA Capital Management, L.P. | $160.94M | 9.77 | 5.05M | +21.34% | +$28.3M | 0.16 | |
| Vr Adviser Llc | $140.18M | 8.51 | 4.4M | +28.5% | +$31.09M | 6.81 | |
| BlackRock | $136.51M | 8.29 | 4.28M | +23.67% | +$26.12M | <0.01 | |
| Bvf Inc Il | $124.97M | 7.59 | 3.92M | -2.12% | -$2.71M | 0.92 | |
| Janus Henderson | $101.84M | 6.18 | 3.2M | +3.37% | +$3.32M | 0.05 | |
| Goldman Sachs | $97.42M | 5.91 | 3.06M | +274.58% | +$71.41M | 0.02 | |
| Deep Track Capital Lp | $96.68M | 5.87 | 3.03M | +32.84% | +$23.9M | 0.44 | |
| Viking Global Investors | $93.51M | 5.68 | 2.93M | -38.7% | -$59.04M | 0.03 | |
| The Vanguard Group | $74.55M | 4.53 | 2.34M | +25.34% | +$15.07M | <0.01 | |
| State Street | $69.4M | 4.21 | 2.18M | +42.93% | +$20.84M | <0.01 | |
| Polar Capital | $57.3M | 3.48 | 1.8M | New | +$57.3M | 0.32 | |
| Morgan Stanley | $49.37M | 3 | 1.55M | -1.22% | -$607,188.10 | <0.01 | |
| Novo Holdings A/S | $44.6M | 2.71 | 1.4M | -6.67% | -$3.19M | 3.12 | |
| Redmile Group | $40.19M | 2.44 | 1.26M | New | +$40.19M | 0.41 | |
| Arrowmark Colorado Holdings Llc | $34.36M | 2.09 | 1.08M | -10.25% | -$3.92M | 0.09 | |
| Braidwell Lp | $33.53M | 2.04 | 1.05M | New | +$33.53M | 1.9 | |
| Fidelity Investments | $30.87M | 1.87 | 968,882 | +26,539.59% | +$30.75M | <0.01 | |
| Geode Capital Management | $27.81M | 1.69 | 872,663 | +12.14% | +$3.01M | <0.01 | |
| Casdin Capital | $25.49M | 1.55 | 800,000 | -22.62% | -$7.45M | 1.26 | |
| Eventide Asset Management | $24.73M | 1.5 | 776,114 | New | +$24.73M | 0.4 | |
| Dimensional Fund Advisors | $23.86M | 1.45 | 748,992 | +7.79% | +$1.72M | 0.01 | |
| Healthcare Of Ontario Pension Plan Trust Fund | $20.42M | 1.24 | 641,000 | +1,076.15% | +$18.69M | 0.06 | |
| LMR PARTNERS LLP | $15.53M | 0.94 | 487,533 | New | +$15.53M | 0.39 | |
| Eagle Health Investments Lp | $14.75M | 0.9 | 462,911 | +5.71% | +$796,499.97 | 2.88 | |
| Assenagon Asset Management S.A. | $13.72M | 0.83 | 430,556 | New | +$13.72M | 0.03 | |
| JPMorgan Chase | $12.82M | 0.78 | 402,541 | -6.03% | -$823,549.19 | <0.01 | |
| Voloridge Investment Management, LLC | $12.14M | 0.74 | 381,079 | +1,835% | +$11.51M | 0.05 | |
| UBS | $11.92M | 0.72 | 374,190 | +334.85% | +$9.18M | <0.01 | |
| Northern Trust | $11.92M | 0.72 | 374,182 | +2.42% | +$281,610.55 | <0.01 | |
| Opaleye Management Inc | $10.96M | 0.67 | 344,123 | +11.55% | +$1.13M | 2.42 | |
| Charles Schwab | $9.63M | 0.58 | 302,205 | +12.49% | +$1.07M | <0.01 | |
| Candriam S C A | $8.57M | 0.52 | 269,000 | +35.86% | +$2.26M | 0.06 | |
| Marshall Wace | $8.21M | 0.5 | 257,746 | New | +$8.21M | 0.01 | |
| Integral Health Asset Management Llc | $7.96M | 0.48 | 250,000 | -33.33% | -$3.98M | 0.8 | |
| Sofinnova | $6.31M | 0.38 | 198,186 | New | +$6.31M | 0.01 | |
| Soleus Capital Management, L.P. | $6.28M | 0.38 | 197,098 | +330.83% | +$4.82M | 0.03 | |
| Rafferty Asset Management Llc | $6.13M | 0.37 | 192,381 | +51.97% | +$2.1M | 0.02 | |
| Wellington Management Company | $5.4M | 0.33 | 169,648 | -6% | -$344,948.27 | <0.01 | |
| Sphera Fund | $5.17M | 0.31 | 162,161 | New | +$5.17M | 0.03 | |
| Citigroup | $4.88M | 0.3 | 153,284 | +271.08% | +$3.57M | <0.01 | |
| Zimmer Partners Lp | $4.42M | 0.27 | 138,800 | New | +$4.42M | 0.1 | |
| Kennedy Capital Management Inc | $4.36M | 0.27 | 136,771 | New | +$4.36M | 0.09 | |
| BNY Mellon | $4.19M | 0.25 | 131,398 | -9.34% | -$431,448.09 | <0.01 | |
| Deutsche Bank | $3.88M | 0.24 | 121,860 | -74.98% | -$11.63M | <0.01 | |
| National Bank Of Canada Fi | $3.11M | 0.23 | 121,000 | New | +$3.11M | 0.01 | |
| Alyeska Investment Group L P | $3.62M | 0.22 | 113,590 | New | +$3.62M | 0.02 | |
| Nuveen | $3.46M | 0.21 | 108,750 | 0% | +$0 | <0.01 | |
| Bank of America | $3.44M | 0.21 | 107,909 | -34.74% | -$1.83M | <0.0001 | |
| Panagora | $3.25M | 0.2 | 102,068 | -1.55% | -$51,071.57 | 0.02 | |
| Baker Bros Advisors LP | $3.19M | 0.19 | 100,000 | New | +$3.19M | 0.02 |